1. Switzerland Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Bachem Holding AG

Bachem Holding AG

BCHMF
Bachem Holding AGUS flagOther OTC
87.34
USD
- -
- -
6.54BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
2.53
2.72
3.08
3.49
3.85
4.16
4.53
5.74
7.1
7.21
7.73
8.07
9.27
Basic EPS, GAAP
0.35
0.43
0.47
0.61
0.62
0.69
0.78
1.12
1.62
1.37
1.5
1.6
1.98
Free Cash Flow per Basic Share
0.55
0.47
0.53
-0.16
-0.22
-0.18
0.49
0.66
-0.27
-0.67
-0.25
-1.84
-0.77
Dividend per Share
0.3
0.35
0.25
0.3
0.35
0.4
0.4
0.6
0.29
0.7
0.75
0.8
0.41
Book Value per Share
4.61
5.03
5.31
5.46
5.57
5.7
5.84
6.59
7.8
8.53
9.54
10.71
12.26
Tangible Book Value per Share
4.84
5.05
5.08
5.25
5.33
5.46
6.28
6.61
15.63
15.68
17.49
18.27
19.08
Basic Weighted Avg Shares
68
68
68
68
68
68
69
70
71
74
75
75
75
Sales/Revenue/Turnover
171
184
209
236
262
282
314
402
503
532
577
605
695
Operating Margin (%)
17.25
18
18.45
19.05
18.68
19.4
19.88
24.05
25.62
23.93
22.41
21.98
24.07
Depreciation Expense
18
19
18
20
21
23
25
26
28
33
37
43
47
Net Income, GAAP
24
29
32
41
42
47
54
78
115
101
112
120
149
Effective Tax Rate (%)
18.32
20.03
14.59
10.2
13.64
14.63
10.28
14.18
12.71
10.16
9.94
11.07
4.86
Profit Margin (%)
13.83
15.8
15.26
17.42
15.97
16.51
17.27
19.42
22.79
18.93
19.38
19.87
21.41
Working Capital
148
161
148
126
115
111
227
215
699
596
677
542
321
LT Debt
- -
- -
- -
- -
- -
- -
60
- -
- -
- -
- -
- -
- -
Total Equity
336
349
353
365
374
384
448
476
1,121
1,170
1,321
1,391
1,458
Return on Invested Capital (%)
6.19
6.93
8.69
9.98
9.35
9.28
10.23
16.01
13.86
9.84
9.27
8.65
11.08
Return on Capital (%)
6.91
8.16
8.66
10.32
9.36
9.31
10.4
16.13
22.23
16.74
16.67
15.87
17.32
Return on Common Equity (%)
7.89
8.93
9.1
11.3
11.17
12.2
13.7
18.05
22.62
17.04
16.68
15.87
17.28

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
19.43%
32.61%
4.83%
Free Cash Flow
9.05%
108.21%
-58.19%
Net Income, GAAP
17.97%
15.41%
23.74%
Sales/Revenue/Turnover
13.03%
11.82%
14.84%
Total Cash Common Dividend
17.22%
13.51%
-48.77%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
577
2024
- -
- -
- -
- -
605
2025
- -
- -
- -
- -
695

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
1.5
2024
- -
- -
- -
- -
1.6
2025
- -
- -
- -
- -
1.98

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.75
2024
- -
- -
- -
- -
0.8
2025
- -
- -
- -
- -
0.41

Company Description

APIChatGPT
CEO
Anne-Kathrin Stoller
Full Time Employees
2,511
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
Hauptstrasse 144 Bubendorf BL Switzerland 4416
IPO Date
Mar 17, 2011
CIK
0001968378
Website
bachem.com
Similar Companies
Livzon Pharmaceutical Group Inc. (LVZPF)
Dynavax Technologies Corporation (DVAX)
Guangdong Zhongsheng Pharmaceutical Co., Ltd. (002317.SZ)
Valiant Laboratories Limited (VALIANTLAB.BO)
Joincare Pharmaceutical Group Industry Co.,Ltd. (600380.SS)
Simply Solventless Concentrates (HASH.V)
Business
Bachem Holding AG (SIX: BANB) is a leading innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides for research, clinical development, and commercial applications in the pharmaceutical and biotechnology industries. Founded in 1971 and headquartered in Bubendorf, Switzerland, the company operates globally through production sites in Europe (Switzerland, UK), the United States (Vista and Torrance, California), and sales offices in Asia, serving customers with products under the Bachem and Clinalfa brands. Its core offerings include catalog peptides (over 5,000 biologically active peptides), custom peptide synthesis, amino acid derivatives, research-grade production, GMP manufacturing of peptide and oligonucleotide new chemical entities (NCEs), commercial APIs (NCEs and generics from grams to tons), cosmetic peptides, diagnostic peptides, biochemistry services, CMC development, quality and regulatory support, project management, analytical capabilities, and supply chain management; the company recently expanded into oligonucleotide-based GMP APIs to leverage synergies with its peptide expertise. Bachem organizes its business into two main segments—Custom Synthesis (encompassing clinical development, commercial NCEs, and generics) and Core Products (research chemicals and specialties)—targeting pharmaceutical companies, biotech firms, diagnostic and cosmetic industries worldwide. In recent developments, the company reported strong first-half 2025 growth with commercial API sales up 32.4% to CHF 168.4 million and clinical development revenue up 36.9% to CHF 123.7 million, raised its full-year sales growth guidance to 13-18%, and invested CHF 129.1 million in capacity expansions across sites, planning over CHF 400 million total for 2025 including a new manufacturing site in Sisslerfeld, Switzerland. Key milestones include the successful Swissmedic inspection of Building K in Bubendorf for GMP batches in late 2025 and commercial ramp-up in 2026, plus the acquisition of adjacent property in Vista, California, to support USD 250 million in US investments from 2026-2030 for high-volume production and Torrance modernization; earlier, it acquired JPT Peptide Technologies in 2020 and formed strategic partnerships with major pharma players for peptide-based therapies.

Company News

APIChatGPT

  • defenseworld.net

    Short Interest in Bachem Holding AG (OTCMKTS:BCHMF) Grows By 45.2%